Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

ESMO

“This is truly a practice-changing study, not just for our patients but for the design of other studies. We can successfully identify candidates for olaparib. We saw a clinically meaningful improvement in outcomes for patients with HRR genetic alterations, driven mainly by BRCA2,” said Eleni Efstathiou, MD, PhD.
“This is exciting data from one of the first studies to be presented that evaluates ceritinib in patients with active brain metastases. Ceritinib had intracranial activity in this trial consistent with its known extracranial activity. Intracranial responses were rapid, high, and durable across all study arms,” said lead investigator Laura Q. Chow, MD, FRCPC.
“Data from 3 clinical trials with various enrollment criteria and that used different PARP inhibitors, 2 of which used a PARP inhibitor plus bevacizumab, led to the same conclusion of the need to expand the use of PARP inhibition in ovarian cancer to all patients. These trials show that the PARP inhibition era is here.”
Barcelona, Spain—Late-breaking data from 2 clinical trials presented at ESMO 2019 will likely change the treatment paradigm for pre- or postmenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer, regardless of menopausal status. The MONALEESA-3 study and the MONARCH-2 study showed an improved overall survival (OS) with the addition of the CDK4/6 inhibitor ribociclib (Kisqali) or abemaciclib (Verzenio) to endocrine therapy as first- or second-line therapy. The results were presented at the Presidential Session of the meeting.
A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer.
A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer.
Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early.
Although the combination of 2 antivascular agents showed preliminary efficacy, increased cardiac toxicity has resulted in premature discontinuation of the trial.
In a prospective trial, the VEGFR-2 small-molecule inhibitor apatinib has shown promising efficacy and safety signals.
Based on the tolerable safety profile established in phase 1b of the ORION-01 trial, the recommended dose for expansion/recommended phase 2 dose of the oregovomab/nivolumab combination immunotherapy has been established.
Page 1 of 3
Results 1 - 10 of 23